Tafamidis ATTR Cm denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Tafamidis Quantity — and Why You Can Appeal

Quantity-limit denials for tafamidis in ATTR-CM typically occur because UnitedHealthcare's coverage policy restricts the number of units dispensed per fill to align with the FDA-approved dosing regimen. If your prescription was written in a way that the plan's system read as exceeding that regimen — or if a fill was submitted outside normal dispensing windows — you will receive this denial even when the therapy is otherwise appropriate.

This is appealable. The FDA-approved prescribing information specifies a single approved dosing schedule. If your prescriber ordered exactly what the label authorizes, the quantity limit should be met and the denial is likely an administrative mismatch, not a clinical one.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 guarantee you a full-and-fair internal review followed by independent external review.
• You generally have 180 days from the denial notice to file an internal appeal.
• If the internal appeal is denied, you have approximately 4 months to request external review by an independent review organization (IRO).
• Expedited review (72-hour decision) is available when standard timelines would seriously jeopardize your health — ATTR-CM is a progressive, life-threatening condition, so expedited review is worth requesting.

## Appeal Timeline

1. Request the denial explanation and the full coverage policy in writing (within 30 days). 2. File a written internal appeal with supporting documentation. 3. UHC must respond within 30 days (non-urgent) or 72 hours (expedited). 4. If denied internally, request external review within the IRO window.

## Documentation to Gather

• Diagnosis confirmation: Pathology or imaging report (e.g., nuclear scintigraphy or biopsy) establishing ATTR-CM; genetic or wild-type classification.
• Prescribing label alignment: A letter from your cardiologist confirming the prescribed quantity matches the FDA-approved regimen exactly — citing the prescribing information.
• Clinical severity: Chart notes documenting functional class, symptom burden, and disease progression.
• Prior treatment history: Dates and outcomes of any prior therapies tried or contraindicated.
• Prescriber medical-necessity letter: Explicit statement that the quantity ordered is consistent with the approved label and medically necessary.

## Criteria-Mapping Structure

Copy each requirement listed in UHC's published medical/coverage policy for tafamidis. For each requirement, insert the exact supporting fact from your medical record:

| Policy Requirement | Chart Evidence | |---|---| | Diagnosis of ATTR-CM confirmed by [method the policy specifies] | [Your diagnostic report date and result] | | Quantity per fill consistent with FDA label | [Prescriber attestation citing label] | | Any additional policy criteria | [Corresponding chart documentation] |

Obtain the exact FDA-approved dosing schedule from the current prescribing information at DailyMed (dailymed.nlm.nih.gov) and confirm your prescription matches it precisely. Then obtain UHC's current coverage policy for tafamidis from UHC's provider portal or by calling the number on your Explanation of Benefits.